Today: 30 April 2026
Browse Category

Pharmaceutical Industry 4 February 2026 - 27 April 2026

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Oruka Therapeutics reported its experimental psoriasis drug ORKA-001 achieved complete skin clearance in 63.5% of patients at 16 weeks. Shares jumped 10.5% to $76.39 before the company launched a $500 million public offering. No serious adverse events were reported in the trial. ORKA-001 is being developed as a long-acting injectable, with annual dosing possible.
27 April 2026
···
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
18 April 2026
··
Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health shares rose to $26.65 Thursday after the FDA said it would reconsider restrictions on several peptides, removing 12 from a high-risk list and scheduling a July review of seven more. The move follows Hims’ March decision to stop advertising compounded GLP-1 drugs and expand branded offerings through Novo Nordisk. The company acquired a California peptide facility last year to bolster supply.
16 April 2026
···
ImmunityBio (IBRX) Stock Tumbles After FDA Warning on Anktiva Claims

ImmunityBio (IBRX) Stock Tumbles After FDA Warning on Anktiva Claims

ImmunityBio shares fell 21.1% Tuesday after the FDA posted a warning letter accusing the company of false or misleading claims about its cancer drug Anktiva in a TV ad and podcast. The FDA said the materials suggested Anktiva could cure or prevent all cancer, which is not approved. ImmunityBio has 15 working days to respond. Anktiva accounted for nearly all of the company’s $113 million in 2025 revenue.
25 March 2026
··
Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics shares jumped 18% Monday after reports that FDA biologics chief Vinay Prasad will depart in April. The move follows the agency’s January rejection of Atara’s EBVALLO therapy for a rare blood cancer, which wiped out 56% of the stock’s value. Atara and partner Pierre Fabre have requested a Type A meeting with the FDA to revisit the decision. Atara ended 2025 with $8.5 million in cash.
9 March 2026
····
Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds

Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds

Capricor Therapeutics shares jumped 7.6% to $30.01 after the company set March 12 for its quarterly and annual update, spotlighting its Duchenne muscular dystrophy therapy, deramiocel. An MDA conference abstract showed deramiocel met main goals in a 106-patient Phase 3 trial, with no imbalance in severe adverse events. The FDA rejected approval in July but later requested the full study report.
9 March 2026
·
Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now

Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now

Day One Biopharmaceuticals shares traded at $21.24 Monday, just below Servier’s $21.50-per-share cash offer in a $2.5 billion takeover. The deal would give Servier Ojemda, the only U.S.-approved single-drug treatment for pediatric low-grade glioma, with 2025 sales of $155.4 million. The tender offer has not started and closing depends on shareholder response and U.S. antitrust clearance.
9 March 2026
Tango Therapeutics stock jumps 36% after Q4 results, Erasca cancer trial pact

Tango Therapeutics stock jumps 36% after Q4 results, Erasca cancer trial pact

Tango Therapeutics shares rose 36% after announcing a collaboration with Erasca to test vopimetostat in pancreatic and lung cancers. The company reported a fourth-quarter net loss of $38.7 million and cash reserves of $343.1 million. Tango plans to start a pivotal pancreatic cancer trial in 2026 and released early efficacy data from ongoing studies.
6 March 2026
···
Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers Health shares rose 0.3% premarket after a 2.3% gain Wednesday, closing at $15.82. The company disclosed in its annual report that it faces an SEC investigation, a Justice Department referral, and a patent lawsuit from Novo Nordisk over compounded semaglutide products. BTIG downgraded the stock, citing regulatory risks and weak guidance. Citi cut its price target to $13.25 and maintained a “sell” rating.
26 February 2026
···
Viking Therapeutics stock (VKTX) slips in premarket after 11% rally as Novo obesity-drug stumble hits tape

Viking Therapeutics stock (VKTX) slips in premarket after 11% rally as Novo obesity-drug stumble hits tape

Viking Therapeutics shares fell 0.5% to $34.30 in premarket trading Tuesday after an 11.1% surge Monday, as investors reacted to new obesity drug trial data from Novo Nordisk. Novo’s CagriSema showed less weight loss than Eli Lilly’s rival drug, shaking the sector. Viking plans to advance its oral obesity drug VK2735 into late-stage trials in Q3. Investors await updates at upcoming healthcare conferences in March and April.
24 February 2026
··
CSL share price slips as buyback tally grows; Lilly deal sets up next week

CSL share price slips as buyback tally grows; Lilly deal sets up next week

CSL shares fell 0.6% to A$153.27 Friday, ending a two-day rebound. The company disclosed a 69,497-share buyback for A$10.7 million and confirmed a new licensing deal with Eli Lilly for clazakizumab, including a $100 million upfront payment. Director Alison Watkins acquired 214 shares under a board plan. Investors are watching buyback pace and updates on the Lilly agreement next week.
20 February 2026
····
Merck stock price hits a 52-week high on Deutsche Bank upgrade as MRK heads into holiday week

Merck stock price hits a 52-week high on Deutsche Bank upgrade as MRK heads into holiday week

Merck shares rose 1.8% to $121.41 Friday after Deutsche Bank upgraded the stock and raised its price target to $150. The stock hit a 52-week high of $123.33 before markets closed for the Presidents Day holiday. Merck plans to present new bladder and kidney cancer data at the ASCO GU meeting later this month. Chief marketing officer Chirfi Guindo sold 10,000 shares earlier in the week, according to a regulatory filing.
15 February 2026
··
Johnson & Johnson stock price: JNJ near 52-week high as talc ruling, heart-device data set up Monday

Johnson & Johnson stock price: JNJ near 52-week high as talc ruling, heart-device data set up Monday

A New Jersey appeals court disqualified Beasley Allen from representing plaintiffs in consolidated state talc cases against Johnson & Johnson; the firm plans to appeal. J&J shares closed up 0.93% at $239.99, near a 52-week high, before slipping slightly after hours. The company also reported positive pilot data for its investigational AFib platform.
8 February 2026
··
Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next

Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next

Roivant Sciences shares surged 22% to $25.82 Friday after the company reported positive Phase 2 data for brepocitinib in cutaneous sarcoidosis and filed for U.S. approval in dermatomyositis. Trading volume exceeded 24 million shares. Roivant posted a quarterly loss of $313.7 million on $2 million in revenue, with $4.5 billion in cash and equivalents.
8 February 2026
·
Cigna stock jumps as earnings beat meets soft 2026 outlook and FTC insulin settlement

Cigna stock jumps as earnings beat meets soft 2026 outlook and FTC insulin settlement

Cigna shares rose 3.2% to $280.46 after posting Q4 adjusted earnings of $8.08 per share, above forecasts, though its 2026 outlook missed estimates. Express Scripts agreed to a 10-year FTC settlement on insulin pricing, expected to cut patient costs by up to $7 billion. Evernorth pharmacy revenue jumped 20% to $36.3 billion. Cigna’s board raised its quarterly dividend to $1.56 per share.
5 February 2026
···
Eli Lilly stock jumps as 2026 forecast beats estimates on Zepbound, Mounjaro demand

Eli Lilly stock jumps as 2026 forecast beats estimates on Zepbound, Mounjaro demand

Eli Lilly shares surged about 9% Wednesday after reporting a 43% jump in quarterly revenue to $19.3 billion and issuing a bullish 2026 outlook. Mounjaro and Zepbound drove results, but executives warned pricing will weigh on future growth. Investors await the FDA’s April decision on Lilly’s oral obesity drug. The stock’s rally contrasted with declines in major indexes.
4 February 2026
···
Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus

Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus

Pfizer shares rose 3.7% to $26.73 Wednesday after reporting Phase 2b trial results showing up to 12.3% placebo-adjusted weight loss at 28 weeks for its obesity drug PF’3944. The company reaffirmed its 2026 revenue and profit targets and said it will not pursue share buybacks. Pfizer reported Q4 adjusted EPS of 66 cents on $17.6 billion revenue. Full VESPER-3 results will be released June 6.
4 February 2026
··
1 2 3 … 9

Stock Market Today

  • Stocks Rally as Nasdaq 100 Hits Record High on Strong Tech Earnings
    April 30, 2026, 1:29 PM EDT. Stocks rose with the Nasdaq 100 reaching a new record high, driven by Alphabet's stronger-than-expected Q1 revenue and Qualcomm's impressive Q2 results, up 6% and 16% respectively. The S&P 500 and Dow also gained, supported by lower crude oil prices that eased inflation concerns and pushed 10-year Treasury yields down. Despite mixed US economic data including a slower GDP growth of 2.0% versus expectations of 2.3%, and mixed signals from manufacturing and leading indicators, the labor market remained strong with initial jobless claims at a 57-year low. Meanwhile, Meta and Microsoft pulled back due to cautious forecasts and growth concerns. Falling oil prices reflect worries about economic growth impacting energy demand.

Latest article

Dow Jones Today: Caterpillar Sparks 700-Point Rally as Wall Street Shrugs Off Oil Shock

Dow Jones Today: Caterpillar Sparks 700-Point Rally as Wall Street Shrugs Off Oil Shock

30 April 2026
The Dow Jones Industrial Average surged nearly 700 points midday Thursday, driven by a 10% jump in Caterpillar shares after strong quarterly results. The S&P 500 and Nasdaq rose modestly as tech stocks lagged. U.S. GDP grew at a 2% annual rate, but inflation data remained above the Fed’s target, limiting rate-cut expectations. Industrials outperformed, while some major tech firms fell on capex concerns.
Dow Jumps 700 Points as US Stock Market Today Shrugs Off Oil Shock and Chases Best Month Since 2020

Dow Jumps 700 Points as US Stock Market Today Shrugs Off Oil Shock and Chases Best Month Since 2020

30 April 2026
The Dow Jones rose 1.48% to 49,584.97 by midday Thursday, outpacing the S&P 500 and Nasdaq as strong corporate earnings pushed major indexes toward their best monthly gains since 2020. First-quarter GDP grew at a 2.0% annual rate, while the core PCE price index climbed 4.3%. The Federal Reserve held rates steady, citing persistent inflation. Alphabet’s Google Cloud revenue surged 63%, while Meta and Microsoft announced large AI-driven spending plans.
Hertz Stock Surges on Uber Robotaxi Deal as Oro Mobility Steps Out of the Shadows

Hertz Stock Surges on Uber Robotaxi Deal as Oro Mobility Steps Out of the Shadows

30 April 2026
Hertz shares surged over 20% Thursday after it launched Oro Mobility, an affiliate set to manage Uber’s robotaxi and human-driven fleets in key U.S. markets. Oro will support Uber’s autonomous program with Lucid vehicles using Nuro self-driving tech, starting in the San Francisco Bay Area later this year. Hertz traded at $6.80, up $1.20; Uber fell 38 cents to $74.09. Hertz reports first-quarter results May 7.
Go toTop